Manages spasticity. ANDA 211798, held by Alkem Laboratories. Tizanidine Hydrochloride.
As of Nov 20, 2026, ANDA 211798 (Tizanidine Hydrochloride), held by Alkem Laboratories, was first approved by FDA on Jan 25, 2019, with 1 approved supplement and 0 published complete response letters.
Tizanidine is a central alpha-2-adrenergic agonist indicated for the management of spasticity. Because of the short duration of therapeutic effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 25, 2019 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · tablet;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 4MG BASE · tablet;oral | Tizanidine Hydrochloride | Rx |
| Sep 26, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 25, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters